Zealand Pharma reports completion of the second and pivotal Phase 3...
Zealand Pharma reports completion of the second and pivotal Phase 3 trial with dasiglucagon for the treatment of severe hypoglycemia Last patient visit concluded in the multinational pivotal Phase 3 trial ahead of previous guidance, with key results now expected in Q3 2018, Dasiglucagon is a potential first-in-class soluble glucagon analog in a ready-to-use rescue pen, the HypoPal A , to treat severe hypoglycemia The first Phase 3 trial with dasiglucagon for treatment of severe hypoglycemia was reported to have successfully met its primary objective in Q1 2018 Copenhagen, Denmark, May 28, 2018 - Zealand Pharma announces that all subjects have been enrolled and dosed in the second and pivotal Phase 3 trial to confirm the clinical efficacy and safety of dasiglucagon for the rescue treatment of severe hypoglycemia in patients with type 1 diabetes.
Start the conversation, or Read more at GlobeNewswire.
|GlucaGen Diagnostic Kit, Glucagon (Aug '12)||Aug '12||Locked_Loaded||2|
|Morphine (generic),GlucaGen Diagnostic... (Aug '12)||Aug '12||nashbright||1|
|acquire your GlucaGen Diagnostic Kit, Glucagon... (Jun '12)||Jun '12||nashbright||1|
|pharmaceutical GlucaGen Diagnostic Kit, Xanax... (Jun '12)||Jun '12||noelspri||1|
|available GlucaGen Diagnostic Kit, Glucagon at... (Jun '12)||Jun '12||derrybright||1|
|Dizziness and Diabetes (Nov '11)||Nov '11||shantilal||1|
|Artificial pancreas works in 11 patients: study (Apr '10)||Apr '10||thakorbhai||1|
Find what you want!
Search Forum Now
Copyright © 2018 Topix LLC